Page 13 - Flipbook

Nolix

• 26F with SUI, cross-over (test with and
without the device)

• Modified 1-h Pad Weight Gain (PWG)

• Clinically meaningful level of

improvement in PWG achieved in

79.5%

• 83% found the Nolix comfortable

• No adverse events reported Conclusion

• Weakness: short time frame (~1 h) The Nolix device served as a

noninvasive, effective, and well-

tolerated treatment option for reducing
SUI in a modified 1-h PWG test with a set

of incontinence-inducing activities